Pneomococcal Vaccine Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Impact of a Letter Encouraging Pneumococcal Vaccination on the 1-year Vaccination Rate in Heart Failure Patients With a Primary Care Physician
Conditions: Chronic Heart Failure Interventions: Other: Incentive letter for pneumococcal vaccination to the patient and to the GP Sponsors: University Hospital, Montpellier Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine
Conditions: Pneumococcal Vaccine Interventions: Biological: MVX01; Biological: MVX01 Placebo Sponsors: Matrivax Research and Development Corporation Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials

Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection: a Retrospective Study in Two Lombardy Centers in the Pre-pandemic Phase From 2015 to 2019.
Conditions: Invasive Pneumococcal Infection Sponsors: Azienda Ospedaliera di Lecco; IRCCS Ospedale San Raffaele Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials

Pneumococcal conjugate vaccination schedules in infants —acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study: statistical analysis plan
We describe the approach to analyses and how we will account for the effect of clustering. Defining the SAP prior to the conduct of analysis will avoid bias in analyses that may arise from prior knowledge of trial findings.Trial registrationISRCTN, ISRCTN7282161328. Registered on 28 November 2019.https://www.isrctn.com/ISRCTN72821613.Protocol: MRCG SCC number 1670, LSHTM Ref 17683.Current protocol version: 6.0, 24 May 2021.Version: 1.0 (5 April 2023); SAP revisions —none. (Source: Trials)
Source: Trials - March 26, 2024 Category: Research Source Type: clinical trials

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
RAHWAY, N.J.--(BUSINESS WIRE) March 19, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive data from multiple Phase 3 studies evaluating V116, the company’s investigational,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 19, 2024 Category: Pharmaceuticals Source Type: clinical trials

Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23
Conditions: Healthy Volunteers Interventions: Biological: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 1); Biological: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 2); Biological: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 3) Sponsors: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials

Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
Conditions: Pneumococcal Vaccines; Immunosuppression Interventions: Drug: 15-valent pneumococcal conjugate vaccine; Drug: 23-valent pneumococcal polysaccharide vaccine Sponsors: VA Sierra Nevada Health Care System; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials

Education to Improve Pneumococcal Vaccine Uptake Among Older Adults
Conditions: Pneumococcal Vaccine Uptake; Vaccination Willingness; Pneumococcal Vaccine Knowledge; Pneumococcal Vaccine Attitude Interventions: Other: Web-based educational video on pneumococcal vaccination; Other: Reminder email to be vaccinated Sponsors: University of Ottawa Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
Conditions: Salmonella Infections Interventions: Biological: Measles and Rubella vaccine; Biological: Yellow Fever vaccine; Biological: Pentavalent vaccine; Biological: Pneumococcal vaccine; Biological: Inactivated polio vaccine; Biological: iNTS-GMMA Dose C; Biological: iNTS-GMMA Dose B; Biological: iNTS-GMMA Dose A; Biological: MenACWY; Combination Product: DTPa-HBV-IPV+Hib; Drug: Placebo Sponsors: GlaxoSmithKline; European& Developing Countries Clinical Trials Partnership; Kwame Nkrumah University of Science and Technology; Pedvac iNTS consortium Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials

Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity
Conditions: Vaccine-Preventable Diseases Interventions: Drug: Pneumococcal Vaccine Sponsors: Leiden University Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Conditions: Pneumococcal Infectious Disease Interventions: Biological: Sinovac PCV13; Biological: PREVNAR 13 Sponsors: Sinovac Research and Development Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2023 Category: Research Source Type: clinical trials

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
Conditions: Pneumococcal Vaccine; Esophageal Cancer; Lymphopenia; Chemoradiation Interventions: Biological: Pneumonia vaccine Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 25, 2023 Category: Research Source Type: clinical trials

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
Conditions: Pneumococcal Disease Interventions: Biological: Multivalent Pneumococcal Vaccine - Formulation 1; Biological: Multivalent Pneumococcal Vaccine - Formulation 2; Biological: 20-valent pneumococcal conjugate vaccine (20vPnC) Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 25, 2023 Category: Research Source Type: clinical trials

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
Conditions: Pneumococcal Infection Interventions: Biological: V116; Biological: PPSV23 Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials

FDA Grants Priority Review to Merck ’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
Acceptance based on results from multiple Phase 3 trials If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults The 21 serotypes covered by V116 are responsible for approximately 83% of invasive... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 19, 2023 Category: Pharmaceuticals Source Type: clinical trials